27 Geographic Atrophy Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Geographic Atrophy Studies in San Francisco

NCT00358943Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatme...

San Francisco, CA12,000 participantsGenzyme, a Sanofi Company

View Study Details

NCT01750619Recruiting

Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions

To evaluate clinical outcome for patients receiving treatment of suspected premalignant and malignant gastrointestinal lesions at Interventional Endoscopy Services. The primary outcome is curative end...

San Francisco, CA8,000 participantsCalifornia Pacific Medical Center Research Institute

View Study Details

NCT06393374Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TP...

San Francisco, CAPHASE31,530 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06080698Recruiting

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy f...

San Francisco, CANA1,030 participantsJohns Hopkins University

View Study Details

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

San Francisco, CAPHASE31,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07392892Recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (sprea...

San Francisco, CAPHASE2840 participantsPfizer

View Study Details

NCT07585266Recruiting

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cau...

San Francisco, CAPHASE3800 participantsGlaxoSmithKline

View Study Details

NCT07221149Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreat...

San Francisco, CAPHASE2690 participantsBristol-Myers Squibb

View Study Details

NCT05208047Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two...

San Francisco, CAPHASE3482 participantsCogent Biosciences, Inc.

View Study Details

NCT07218926Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) w...

San Francisco, CAPHASE3450 participantsGlaxoSmithKline

View Study Details

NCT03827694Recruiting

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI)....

San Francisco, CA400 participantsArkansas Children's Hospital Research Institute

View Study Details

NCT05377996Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors...

San Francisco, CAPHASE1360 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT04540107Recruiting

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopi...

San Francisco, CAPHASE1300 participantsSusan Chang

View Study Details

NCT07831317Recruiting

Multi-strain Probiotic Supplement for Digestive Comfort and Well-being in Healthy Women

This study looks at whether a daily probiotic supplement can help improve mild-to-moderate stomach and digestive symptoms, such as gas and bloating, in women who also experience symptoms commonly asso...

San Francisco, CANA160 participantsDaily Nouri

View Study Details

NCT06658002Recruiting

Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal k...

San Francisco, CAPHASE3150 participantsUniversity of California, San Francisco

View Study Details

NCT06774027Recruiting

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple n...

San Francisco, CA100 participantsUniversity of California, San Francisco

View Study Details

NCT07407777Recruiting

Evaluation of Gut-Related Well-Being and Mood Effects of a Daily Nutritional Food Ingredient From the Co-Fermentation of Fungal Mycelium (Pleurotus Pulmonarius) and Microalgae (Chlorella Vulgaris)

The purpose of the study is to evaluate the gut-related well-being and mood effects of a food ingredient obtained from the co-fermentation of oyster mushroom mycelium (Pleurotus pulmonarius), microalg...

San Francisco, CANA80 participantsKoralo GmbH

View Study Details

NCT06445322Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials....

San Francisco, CA50 participantsAscidian Therapeutics, Inc

View Study Details

NCT04485559Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by t...

San Francisco, CAPHASE150 participantsUniversity of California, San Francisco

View Study Details

NCT07421596Recruiting

An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System

This clinical research study is being conducted to evaluate gut and digestive health before and after the use of a dietary supplement system over an eight-week period. Gut and digestive health play a...

San Francisco, CANA50 participantsSF Research Institute, Inc.

View Study Details

NCT07223944Recruiting

A Gaucher Disease Gene Therapy Trial With FLT201

This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate re...

San Francisco, CAPHASE345 participantsSpur Therapeutics

View Study Details

NCT04434040Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

San Francisco, CAPHASE240 participantsDana-Farber Cancer Institute

View Study Details

NCT07199465Recruiting

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the stu...

San Francisco, CAPHASE140 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05858645Recruiting

Correction of Psoriatic T Cell Signatures by Deucravacitinib

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib....

San Francisco, CAPHASE425 participantsUniversity of California, San Francisco

View Study Details

NCT03266640Recruiting

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovi...

San Francisco, CAPHASE220 participantsNew York Medical College

View Study Details

NCT06467344Recruiting

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for...

San Francisco, CAPHASE115 participantsAscidian Therapeutics, Inc

View Study Details

NCT05390515Recruiting

Psoriatic Immune Response to Tildrakizumab

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab....

San Francisco, CAPHASE410 participantsUniversity of California, San Francisco

View Study Details

About Geographic Atrophy Clinical Trials in San Francisco

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 27 geographic atrophy clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 28,717 participants. Research is being sponsored by Genzyme, a Sanofi Company, California Pacific Medical Center Research Institute, Merck Sharp & Dohme LLC and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in San Francisco — FAQ

Are there geographic atrophy clinical trials in San Francisco?

Yes, there are 27 geographic atrophy clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 27 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated October 15, 2026 from ClinicalTrials.gov